Elisabeth Richard BD Consulting offers a business development (France and International) expertise in the fields of health and innovation having... View Article
Author Archives for Adeline Chauvigné
New member | Elisabeth Richard Business Development Consulting
5 May 2024Elisabeth Richard BD Consulting offers a business development (France and International) expertise in the fields of health and innovation having... View Article
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
VLA2001 successfully met both co-primary endpoints Superior neutralizing antibody titer levels compared to active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S) Neutralizing... View Article
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
5 May 2024VLA2001 successfully met both co-primary endpoints Superior neutralizing antibody titer levels compared to active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S) Neutralizing... View Article
Owkin joins OPTIMA: new research project to improve the treatment of prostate, breast and lung cancer patients using AI
Owkin is delighted to be part of OPTIMA (Optimal Treatment for Patients with Solid Tumours in Europe Through Artificial intelligence),... View Article
Owkin joins OPTIMA: new research project to improve the treatment of prostate, breast and lung cancer patients using AI
5 May 2024Owkin is delighted to be part of OPTIMA (Optimal Treatment for Patients with Solid Tumours in Europe Through Artificial intelligence),... View Article
Hawkcell & Cynbiose team up in a strategic partnership
Cynbiose SAS, a preclinical CRO, and HawkCell, a young innovative company specialized in MRI (Magnetic Resonance Imaging) for small and... View Article
Hawkcell & Cynbiose team up in a strategic partnership
5 May 2024Cynbiose SAS, a preclinical CRO, and HawkCell, a young innovative company specialized in MRI (Magnetic Resonance Imaging) for small and... View Article
OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®
Further Strengthens Global Intellectual Property Portfolio for Tedopi® until 2038 OSE Immunotherapeutics announced today that it has received notice of... View Article
OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®
5 May 2024Further Strengthens Global Intellectual Property Portfolio for Tedopi® until 2038 OSE Immunotherapeutics announced today that it has received notice of... View Article
Atlanpole Biotherapies – spearheading the development of tomorrow’s healthcare industry
2020/2021: THE CLUSTER IS COMMITTED TO SUPPORTING ITS MEMBERS Faced with the current health crisis, cluster members rallied strongly and... View Article
Atlanpole Biotherapies – spearheading the development of tomorrow’s healthcare industry
5 May 20242020/2021: THE CLUSTER IS COMMITTED TO SUPPORTING ITS MEMBERS Faced with the current health crisis, cluster members rallied strongly and... View Article
Focus on the Atlanpole Biotherapies 2021 General Assembly
The 2021 General Assembly was attended by close to 150 people, providing an opportunity to review and assess the cluster’s... View Article
Focus on the Atlanpole Biotherapies 2021 General Assembly
5 May 2024The 2021 General Assembly was attended by close to 150 people, providing an opportunity to review and assess the cluster’s... View Article
Agrocampus Ouest and DelleD create the “AgroHealth Innovation” Chair
DelleD and the Agrocampus Ouest Foundation have joined forces to create “AgroHealth” corporate chair. The aim is to elaborate an... View Article
Agrocampus Ouest and DelleD create the “AgroHealth Innovation” Chair
5 May 2024DelleD and the Agrocampus Ouest Foundation have joined forces to create “AgroHealth” corporate chair. The aim is to elaborate an... View Article
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate
Valneva, a specialty vaccine company, and Pfizer Inc. (NYSE: PFE), today announced further positive Phase 2 results, including booster response,... View Article
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate
5 May 2024Valneva, a specialty vaccine company, and Pfizer Inc. (NYSE: PFE), today announced further positive Phase 2 results, including booster response,... View Article
Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candidate VLA2001
Commences recruitment of Adolescents into Phase 3 trial “Cov-Compare” Enrolls participants in the Phase 1/2 Booster Trial Valneva, a specialty vaccine... View Article
Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candidate VLA2001
5 May 2024Commences recruitment of Adolescents into Phase 3 trial “Cov-Compare” Enrolls participants in the Phase 1/2 Booster Trial Valneva, a specialty vaccine... View Article